NCT04241276 - A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

June 29, 2028

Study Completion Date

February 28, 2029

Conditions

Pancreatic Cancer

Interventions

DRUG

ATRA

45 mg/m2 orally (in two divided doses) from days 1 to 15 of each cycle

DRUG

Gemcitabine

1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle

DRUG

nab-paclitaxel

125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle

Trial Locations (1)

Barts NHS Trust, London